AUTL Relative Valuation
AUTL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AUTL is overvalued; if below, it's undervalued.
Historical Valuation
Autolus Therapeutics PLC (AUTL) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.08. The fair price of Autolus Therapeutics PLC (AUTL) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：1.52
Fair
-1.72
PE
1Y
3Y
5Y
Trailing
Forward
-1.46
EV/EBITDA
Autolus Therapeutics PLC. (AUTL) has a current EV/EBITDA of -1.46. The 5-year average EV/EBITDA is -2.07. The thresholds are as follows: Strongly Undervalued below -5.45, Undervalued between -5.45 and -3.76, Fairly Valued between -0.37 and -3.76, Overvalued between -0.37 and 1.32, and Strongly Overvalued above 1.32. The current Forward EV/EBITDA of -1.46 falls within the Historic Trend Line -Fairly Valued range.
-1.68
EV/EBIT
Autolus Therapeutics PLC. (AUTL) has a current EV/EBIT of -1.68. The 5-year average EV/EBIT is -1.81. The thresholds are as follows: Strongly Undervalued below -4.95, Undervalued between -4.95 and -3.38, Fairly Valued between -0.24 and -3.38, Overvalued between -0.24 and 1.33, and Strongly Overvalued above 1.33. The current Forward EV/EBIT of -1.68 falls within the Historic Trend Line -Fairly Valued range.
3.32
PS
Autolus Therapeutics PLC. (AUTL) has a current PS of 3.32. The 5-year average PS is 134.12. The thresholds are as follows: Strongly Undervalued below -203.02, Undervalued between -203.02 and -34.45, Fairly Valued between 302.69 and -34.45, Overvalued between 302.69 and 471.26, and Strongly Overvalued above 471.26. The current Forward PS of 3.32 falls within the Historic Trend Line -Fairly Valued range.
-1.97
P/OCF
Autolus Therapeutics PLC. (AUTL) has a current P/OCF of -1.97. The 5-year average P/OCF is -3.86. The thresholds are as follows: Strongly Undervalued below -9.13, Undervalued between -9.13 and -6.50, Fairly Valued between -1.23 and -6.50, Overvalued between -1.23 and 1.40, and Strongly Overvalued above 1.40. The current Forward P/OCF of -1.97 falls within the Historic Trend Line -Fairly Valued range.
-2.11
P/FCF
Autolus Therapeutics PLC. (AUTL) has a current P/FCF of -2.11. The 5-year average P/FCF is -3.32. The thresholds are as follows: Strongly Undervalued below -7.64, Undervalued between -7.64 and -5.48, Fairly Valued between -1.16 and -5.48, Overvalued between -1.16 and 1.00, and Strongly Overvalued above 1.00. The current Forward P/FCF of -2.11 falls within the Historic Trend Line -Fairly Valued range.
Autolus Therapeutics PLC (AUTL) has a current Price-to-Book (P/B) ratio of 1.48. Compared to its 3-year average P/B ratio of 2.43 , the current P/B ratio is approximately -38.88% higher. Relative to its 5-year average P/B ratio of 2.05, the current P/B ratio is about -27.60% higher. Autolus Therapeutics PLC (AUTL) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -34.25%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -35.89% , the current FCF yield is about -100.00% lower.
1.57
P/B
Median3y
2.43
Median5y
2.05
-72.41
FCF Yield
Median3y
-34.25
Median5y
-35.89
Competitors Valuation Multiple
The average P/S ratio for AUTL's competitors is 0.00, providing a benchmark for relative valuation. Autolus Therapeutics PLC Corp (AUTL) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of AUTL decreased by 33.19% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 0.00 to 21.19M.
The secondary factor is the Margin Expansion, contributed -80.49%to the performance.
Overall, the performance of AUTL in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Autolus Therapeutics PLC (AUTL) currently overvalued or undervalued?
What is Autolus Therapeutics PLC (AUTL) fair value?
How does AUTL's valuation metrics compare to the industry average?
What is the current P/B ratio for Autolus Therapeutics PLC (AUTL) as of Dec 05 2025?
What is the current FCF Yield for Autolus Therapeutics PLC (AUTL) as of Dec 05 2025?
What is the current Forward P/E ratio for Autolus Therapeutics PLC (AUTL) as of Dec 05 2025?